Trials (Jan 2024)

Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial

  • Xinlun Tian,
  • Yan Xu,
  • Luo Wang,
  • Chongya Dong,
  • Xiaoyan Yan,
  • Junping Fan,
  • Huaiya Xie,
  • Hong Zhang,
  • Jinglan Wang,
  • Yongjian Liu,
  • Yaqi Wang,
  • Siqi Pan,
  • Aohua Wu,
  • Xueqi Liu,
  • Chen Yao,
  • Mengzhao Wang

DOI
https://doi.org/10.1186/s13063-024-07914-3
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Severe acute respiratory syndrome coronavirus 2 will coexist with humans for a long time, and it is therefore important to develop effective treatments for coronavirus disease 2019 (COVID-19). Recent studies have demonstrated that antiviral therapy is a key factor in preventing patients from progressing to severe disease, even death. Effective and affordable antiviral medications are essential for disease treatment and are urgently needed. Azvudine, a nucleoside analogue, is a potential low-cost candidate with few drug interactions. However, validation of high-quality clinical studies is still limited. Methods This is a multicentre, randomized, double-blind, placebo-controlled phase III clinical trial involving 1096 adult patients with mild-to-moderate symptoms of COVID-19 who are at high risk for progression to severe COVID-19. Patients will be randomized to (1) receive azvudine tablets 5 mg daily for a maximum of 7 days or (2) receive placebo five tablets daily. All participants will be permitted to use a standard treatment strategy except antiviral therapy beyond the investigational medications. The primary outcome will be the ratio of COVID-19-related critical illness and all-cause mortality among the two groups within 28 days. Discussion The purpose of this clinical trial is to determine whether azvudine can prevent patients at risk of severe disease from progressing to critical illness and death, and the results will identify whether azvudine is an effective and affordable antiviral treatment option for COVID-19. Trial registration ClinicalTrials.gov NCT05689034. Registered on 18 January 2023.

Keywords